Search

everythinglearnresearchcommunity

for

Search:↓

Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.

JAK inhibitors show promise for treating various skin diseases.

Omalizumab is generally safe for chronic urticaria, but hair loss is a common side effect.

A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.

A woman with a type of hair loss saw hair regrowth after two months of taking baricitinib.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.

Abatacept may help some people with alopecia areata regrow hair.

Early intervention is important for limited systemic sclerosis patients due to higher pain and ulceration risks.

Tofacitinib improved hair and nail conditions in a teen with alopecia areata.

Oral tacrolimus helped a rheumatoid arthritis patient regrow hair lost due to alopecia areata.

Budesonide is not effective for maintaining remission in Crohn's disease beyond three months.

Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.

Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.

Dupilumab effectively controls symptoms in infants with Netherton syndrome.

Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.

Thalidomide works best for skin lupus not helped by antimalarials, but has many side effects; other treatments are less effective, especially if patients also have systemic lupus.

Ritlecitinib effectively treats alopecia areata with manageable side effects.

JAK1 inhibitor may effectively treat alopecia areata when TNF-α inhibitors and corticosteroids fail.

Adalimumab effectively stabilized severe folliculitis decalvans, preventing further hair loss and inflammation.

JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.

Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.

Hydroxychloroquine may cause false results in tuberculosis tests for patients with autoimmune skin diseases.

Mycophenolate mofetil is effective for treating severe lupus nephritis in children.

Dupilumab may help treat hair loss and skin color loss in some patients with atopic dermatitis.

Thiopurines help treat IBD but require genetic testing to avoid side effects.

Ruxolitinib can cause a delayed skin reaction on the nose.

No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.

Baricitinib is the most effective treatment for alopecia areata.

A patient's grey hair regained color during treatment with adalimumab.

People on immune-modifying skin disease treatments may have a weaker antibody response to COVID-19 vaccines but often improve after the second dose.